Université catholique de Louvan – UCL
Centre for Applied Molecular Technologies – CTMA
Brief Biography of Organisation:
UCL-CTMA platform organisation: CTMA (Centre for Applied Molecular Technologies, http://www.uclouvain.be/ctma.htlm) is a clinical research-oriented biotechnological platform of the Université catholique de Louvain (UCL; www.uclouvain.be). UCL-CTMA is a joint academic-clinical-military R&D biotechnological platform. This platform, which focuses on applied science and technological transfer, consists of three distinct pillars which mutualize their respective resources:
- Institut de Recherche Expérimentale et Clinique (IREC/UCL) which is the civilian UCL academic pillar.
- CBRN-Defense Laboratories Department for the BE-Defence (DLD/BE-MOD) which is the military CBRN research and CBRN operational pillar working for DLD.
- St Luc academic hospital (Cliniques Universitaires St Luc, CUSL) supported by CTMA for development and molecular genetics testing and associated clinical research.
Role Organisation will play within project:
UCL-CTMA plays most active role in the project , leading Task 2.5 – Identification and mapping of laboratory data for pandemic detection and monitoring including Next Generation Sequencing (NGS) data and integration with other data sources, and Task 4.6 Improve biosafety and biosecurity, contributing with its expertise and advanced technological methods in pathogens detection, identification, monitoring, decontamination, medical data collection and secure transmission. Having extensive in-field experience with deployable laboratory, UCL-CTMA contributes to the operational strategy development in pandemic preparedness (Task 6.5). Leading a few strategic projects and having strong links with European stakeholders, UCL-CTMA will establish connection with appropriate professionals and organisations for policy discussion on pandemic preparedness and response in the EU and potential for project outputs to strengthen capacity for cross border planning, risk assessment, data sharing and response.